Carla Kriwet is leaving Fresenius Medical Care after two months as CEO

Carla Kriwet

Strategic differences are cited as the reason for her departure from Fresenius Medical Care.

(Photo: BSH Hausgeräte GmbH)

Carla Kriwet is giving up the CEO post at the dialysis group Fresenius Medical Care after just two months. The successor with immediate effect will be Helen Giza, 54, who has previously been Chief Financial Officer and who is already Deputy CEO.

According to the official announcement, Kriwet, 51, is leaving the company at his own request and by mutual agreement due to strategic differences. According to Handelsblatt information from company circles, different views with the management team and the supervisory board around Fresenius boss Michael Sen were decisive. This also involved shaping the transformation and restructuring process of Fresenius Medical Care.

The new FMC boss Helen Giza, born in 1968, gained a reputation as a transformation manager through her work for the pharmaceutical company Takeda before Fresenius Medical Care. In her previous role at FMC, she played a key role in shaping the new corporate structure, which envisaged a change from four world regions to the two global business areas of dialysis services and products. As part of the transformation, Fresenius Medical Care announced last year that 5,000 jobs would be cut worldwide.

The Dax group FMC is the largest division of the health care group Fresenius, which has been managed by long-time Siemens manager Michael Sen since the beginning of October. “In a fundamentally healthy industry, Fresenius Medical Care must focus even more on the operational turnaround, further improve corporate performance and concentrate on its core,” Sen is quoted as saying in the management change announcement.

Top jobs of the day

Find the best jobs now and
be notified by email.

FMC has suffered greatly from the stress of the corona pandemic in recent years and has lost a disproportionately large number of patients. In addition, there were rising costs for hygiene measures and staff shortages due to the pandemic. FMC contributes almost half of the mother’s sales. Fresenius controls FMC via the construction of a partnership limited by shares, but only holds 32 percent of the shares.

Helen Giza

The former Chief Financial Officer of Fresenius Medical Care is now taking over the CEO post.

(Photo: Fresenius)

The dialysis subsidiary is crucial to the success of the healthcare group. The latest profit warnings from Fresenius were mainly due to the problems at Fresenius Medical Care in the USA.

The experienced health manager Kriwet had already worked for the medical technology company Philips for many years. She was the preferred candidate of former Fresenius boss Stephan Sturm to succeed long-time CEO Rice Powell. Although she officially took office on October 1, 2022, the manager had been taking a close look at the company and the situation of the dialysis clinics since the announcement of her appointment in May.

After last unsuccessful actions and another profit warning in the summer, Sturm had to give up his CEO post at the end of September. Michael Sen, head of the Fresenius nutrition division Kabi, took on the role.

Kriwet gave up her managerial position at BSH Hausgeräte GmbH after around two years to take up the post at FMC. From 2013 to 2020 she worked for the healthcare group Philips, where she was responsible for the Connected Care division as a member of the board between 2017 and 2020. Before Philips, she was a board member at the medical technology company Dräger, held several management positions in the strategy department and in the healthcare division of Linde AG and worked as a consultant for the Boston Consulting Group.

More: Fresenius collects profit forecast and reviews its portfolio – shares rise

source site-12